| Literature DB >> 34141082 |
Michael G Yang1, Zili Xiao1, Rulin Zhao1, Andrew J Tebben1, Bei Wang1, Robert J Cherney1, Douglas G Batt1, Gregory D Brown1, Mary Ellen Cvijic1, John V Duncia1, Michael A Gallela1, Daniel S Gardner1, Purnima Khandelwal1, Mary F Malley1, Jian Pang1, Anne V Rose1, Joseph B Santella1, Amy A Sarjeant1, Songmei Xu1, Arvind Mathur1, Sandhya Mandlekar1, Ragini Vuppugalla1, Qihong Zhao1, Percy H Carter1.
Abstract
To improve the metabolic stability profile of BMS-741672 (1a), we undertook a structure-activity relationship study in our trisubstituted cyclohexylamine series. This ultimately led to the identification of 2d (BMS-753426) as a potent and orally bioavailable antagonist of CCR2. Compared to previous clinical candidate 1a, the tert-butyl amine 2d showed significant improvements in pharmacokinetic properties, with lower clearance and higher oral bioavailability. Furthermore, compound 2d exhibited improved affinity for CCR5 and good activity in models of both monocyte migration and multiple sclerosis in the hCCR2 knock-in mouse. The synthesis of 2d was facilitated by the development of a simplified approach to key intermediate (4R)-9b that deployed a stereoselective reductive amination which may prove to be of general interest.Entities:
Year: 2021 PMID： 34141082 PMCID： PMC8201760 DOI： 10.1021/acsmedchemlett.1c00082
Source DB: PubMed Journal: ACS Med Chem Lett ISSN： 1948-5875 Impact factor: 4.632